Literature DB >> 21095465

Catechol-O-methyltransferase and pain.

Oleg Kambur1, Pekka T Männistö.   

Abstract

In animals, different types of COMT inhibitors, irrespective of their brain penetration, are pro-nociceptive in several models of acute and inflammatory pain. Similarly, COMT knock-out mice are more sensitive to nociceptive stimuli, whereas in mice over-expressing a high activity COMT variant nociceptive sensitivity is decreased. COMT knock-out mice also show altered response to opioids and stress-induced analgesia. In different rat models of neuropathic pain, the action of nitecapone is opposite: it is antinociceptive and antiallodynic. Complex actions of low COMT activity may be caused by enhanced adrenergic and dopaminergic activities that play different and even contrasting roles at different parts of the nociceptive system. Also compensatory changes in other neurotransmitters may occur. Pro-nociceptive effects seem to be caused by increased activation of peripheral adrenergic β(2)- and β(3) -receptors. Other properties of COMT inhibitors, like scavenging of oxygen and nitrogen radicals, may be important in antiallodynic effects found in neuropathic pain models. Increased number of µ-opioid receptors in certain brain areas may be responsible of enhanced opioid effects associated with a low COMT activity. In human pain studies, a low COMT activity is often associated with increased pain sensitivity in experimental pain models and with increased pre- and postoperative pain in acute clinical situations. As a rule, a simultaneous occurrence of several SNPs within the haplotype, causing low COMT activity, is more often associated with pain than any single SNP alone. In experimental pain studies, all negative findings resulted from concentrating solely on SNP rs4680 (Val158Met). Virtually all studies assessing haplotypes were able to confirm an association of a low COMT and increased pain. In chronic clinical pain, the effect of COMT polymorphisms depends on the pain conditions. Hence, in neuropathic and cancer pains, COMT activity is meaningless but in some chronic musculoskeletal pain conditions and migraine or headache low COMT activity appears to increase incidence and symptoms. A low COMT activity also increases availability of opioid receptors and may enhance opioid analgesia and adverse effects at least in cancer pains.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21095465     DOI: 10.1016/B978-0-12-381326-8.00010-7

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  19 in total

Review 1.  A systematic review of the association between immunogenomic markers and cancer-related fatigue.

Authors:  L N Saligan; H S Kim
Journal:  Brain Behav Immun       Date:  2012-05-14       Impact factor: 7.217

Review 2.  The phenotypic and genetic signatures of common musculoskeletal pain conditions.

Authors:  Luda Diatchenko; Roger B Fillingim; Shad B Smith; William Maixner
Journal:  Nat Rev Rheumatol       Date:  2013-04-02       Impact factor: 20.543

Review 3.  Janus molecule I: dichotomous effects of COMT in neuropathic vs nociceptive pain modalities.

Authors:  S K Segall; W Maixner; I Belfer; T Wiltshire; Z Seltzer; L Diatchenko
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-05       Impact factor: 4.388

4.  Proteomic analysis on the alteration of protein expression in the early-stage placental villous tissue of electromagnetic fields associated with cell phone exposure.

Authors:  Qiong Luo; Ying Jiang; Min Jin; Jian Xu; He-Feng Huang
Journal:  Reprod Sci       Date:  2013-02-18       Impact factor: 3.060

Review 5.  Personalized medicine and opioid analgesic prescribing for chronic pain: opportunities and challenges.

Authors:  Stephen Bruehl; A Vania Apkarian; Jane C Ballantyne; Ann Berger; David Borsook; Wen G Chen; John T Farrar; Jennifer A Haythornthwaite; Susan D Horn; Michael J Iadarola; Charles E Inturrisi; Lixing Lao; Sean Mackey; Jianren Mao; Andrea Sawczuk; George R Uhl; James Witter; Clifford J Woolf; Jon-Kar Zubieta; Yu Lin
Journal:  J Pain       Date:  2013-02       Impact factor: 5.820

6.  Effect of catechol-o-methyltransferase-gene (COMT) variants on experimental and acute postoperative pain in 1,000 women undergoing surgery for breast cancer.

Authors:  Oleg Kambur; Mari A Kaunisto; Emmi Tikkanen; Suzanne M Leal; Samuli Ripatti; Eija A Kalso
Journal:  Anesthesiology       Date:  2013-12       Impact factor: 7.892

7.  An imaging genetics approach to understanding social influence.

Authors:  Emily B Falk; Baldwin M Way; Agnes J Jasinska
Journal:  Front Hum Neurosci       Date:  2012-06-12       Impact factor: 3.169

Review 8.  Placebo, nocebo, and neuropathic pain.

Authors:  Lene Vase; Ina Skyt; Kathryn T Hall
Journal:  Pain       Date:  2016-02       Impact factor: 7.926

9.  A polygenic score for acute vaso-occlusive pain in pediatric sickle cell disease.

Authors:  Evadnie Rampersaud; Guolian Kang; Lance E Palmer; Sara R Rashkin; Shuoguo Wang; Wenjian Bi; Nicole M Alberts; Doralina Anghelescu; Martha Barton; Kirby Birch; Nidal Boulos; Amanda M Brandow; Russell John Brooke; Ti-Cheng Chang; Wenan Chen; Yong Cheng; Juan Ding; John Easton; Jason R Hodges; Celeste K Kanne; Shawn Levy; Heather Mulder; Ashwin P Patel; Latika Puri; Celeste Rosencrance; Michael Rusch; Yadav Sapkota; Edgar Sioson; Akshay Sharma; Xing Tang; Andrew Thrasher; Winfred Wang; Yu Yao; Yutaka Yasui; Donald Yergeau; Jane S Hankins; Vivien A Sheehan; James R Downing; Jeremie H Estepp; Jinghui Zhang; Michael DeBaun; Gang Wu; Mitchell J Weiss
Journal:  Blood Adv       Date:  2021-07-27

Review 10.  Systems and Circuits Linking Chronic Pain and Circadian Rhythms.

Authors:  Andrew E Warfield; Jonathan F Prather; William D Todd
Journal:  Front Neurosci       Date:  2021-07-02       Impact factor: 5.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.